RNAi Matures in 2013 amid New Delivery Approaches, Renewed Interest by Big Pharma | GenomeWeb

For RNAi, 2013 proved to be a year largely marked by incremental successes that, while not always the most attention grabbing, reflect the maturity of the gene-silencing technology and have helped it begin to reignite the interest of big pharma in RNA therapeutics.

It was during the past year that RNAi — indeed, RNA therapeutics in general — "have come of age," Regulus Therapeutics CEO Kleanthis Xanthopoulos told Gene Silencing News. "There is no longer skepticism about whether the … approach works."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: genome sequencing study of Yakutian horses, tardigrade genome, and more.

A guest post at Retraction Watch discusses what funders can do to improve research reproducibility.

Researchers report in Nature this week that farming led to genomic adaptations in humans.

The FDA argues that it needs to evaluate the safety and efficacy of laboratory-developed tests, a proposal that divides Republicans.

Sponsored by
HTG Molecular

This webinar will discuss potential clinical applications for miRNA signatures and a novel, extraction-free miRNA profiling technology for advancing biomarker discovery.